The presentation of positive interim results at a major symposium like ASCO can be a significant catalyst for biotech stocks. If Adagene's ADG126 shows promising efficacy and safety profiles, it could lead to increased investor confidence and a rise in stock price. However, the impact is also contingent on the market's expectations and the current performance of the drug in trials.